Puma Biotechnology Inc (NASDAQ: PBYI). Significant positive changes in investment behavior have recently occurred: the stock rose on very heavy volume.
Puma Biotechnology Inc (NASDAQ: PBYI). Notable positive changes in fundamentals have recently occurred: the consensus estimate for December, 2023 increased significantly, the stock’s power rating rose above 70, and the consensus estimate for December, 2024 increased significantly.
In light of these very positive signals we are reviewing our current Overall Rating of B. We would continue to view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, PBYI is expected to continue to be a major Value Builder.
Puma Biotechnology has a current Value Trend Rating of B (Positive). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Puma Biotechnology has a slightly positive Appreciation Score of 61 and a good Power Rating of 78, with the Positive Value Trend Rating the result.
Recent Price Action
On 11/30/23, Puma Biotechnology Inc (NASDAQ: PBYI) stock rose modestly by 0.5%, closing at $3.90. Moreover, exceptionally high trading volume at 224% of normal accompanied the advance. The stock has risen 1.3% during the last week and has been strong relative to the market over the last nine months.
Be the first to comment